Access cutting-edge triple-negative breast cancer treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access triple-negative breast cancer specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related triple-negative breast cancer treatment provided free
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Sponsor: AstraZeneca
Check if you qualify for this triple-negative breast cancer clinical trial in New Haven, CT
If you're searching for triple-negative breast cancer treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced triple-negative breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.